A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)

  • Lee J
  • Annunziata C
  • Houston N
  • et al.
N/ACitations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The PARP inhibitor, olaparib (O) showed clinical activity in subsets of recurrent OvCa patients (pts). We hypothesized increased DNA damage by O may complement anti-tumor activity of immune checkpoint blockade, durvalumab (D) in recurrent OvCa. We previously reported the safety data and recommended phase 2 dose (RP2D) of D+O. Enrollment in the phase 2 OvCa cohort was completed April 2018 and results are presented here (NCT02484404). Methods: Eligible pts with PS 0-1, good end organ function and biopsiable disease received the RP2D (O 300 mg orally twice daily and D 1500mg IV) on day 1 of each 28- day cycle. The primary objective was to estimate clinical activity using RECIST v1.1 response rate (RR) and a 2-stage design targeting 35 evaluable pts. Safety was assessed by CTCAEv4.0. Tissue and blood samples were collected pre-treatment and on therapy (cycle 1 day 15 and cycle 3 day 1). Results: 35 pts received at least 1 cycle of treatment (median age 67 year-old [range 40- 85], 6 germline BRCA mutation carriers [gBRCAm; 17%]/29 BRCA wild type [BRCAwt; 83%]). 30 pts (86%) had platinum-resistant recurrent disease. Median number of prior therapy regimens was 3.5 (1-16). Among 34 evaluable pts (6 gBRCAm/28 BRCAwt), 5 PRs were observed (15% RR, median 11months [6.5-23]): 2 pts with gBRCAm (platinum-resistant [8.5months] and -sensitive disease [11+months]) and 3 pts with BRCAwt (platinum-resistant [2; 23 and 14+months] and -sensitive disease [6.5months]). 13 pts (3 gBRCAm/10 BRCAwt) had SD>=4months (median 6.5months [4-12.5]), yielding 53% disease control rate (PR+SD>=4months). Grade 3/4 adverse events include anemia (26%) and lymphopenia (14%). 3 pts required O dose reduction due to grade 3 anemia (1), grade 3 atrial fibrillation (1) and recurrent grade 2 nausea refractory to supportive care (1). PD-L1 expression/TIL by immunohistochemistry, DNA repair deficiency by a BROCA-HR panel, and immune subsets by flow cytometry will be presented. Conclusions: Our results suggested D+O was well-tolerated and had clinical activity in a subgroup of heavily pretreated BRCAwt OvCa pts. Biomarker evaluation is ongoing to further characterize the subset of pts who had benefit from D+O.

Cite

CITATION STYLE

APA

Lee, J.-M., Annunziata, C. M., Houston, N., Kohn, E. C., Lipkowitz, S., Minasian, L., … Zimmer, A. D. S. (2018). A phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa). Annals of Oncology, 29, viii334. https://doi.org/10.1093/annonc/mdy285.145

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free